Latest Loan Facilities News

Hydrix Limited narrowed its FY2025 loss to $2.92 million, driven by significant cost reductions and steady revenue from expanding international medtech clients. Despite ongoing challenges in sales cycles and funding, the company remains focused on innovation and strategic investments.

Zelira Therapeutics reported a significantly reduced loss of AUD 3.85 million for FY25, driven by clinical progress and strategic funding for its HOPE® cannabinoid medicines. The company also expanded its patent portfolio and commercial footprint across key markets.

KneoMedia has narrowed its FY25 net loss by 38%, driven by cost controls and a strategic shift to its scalable KneoScience EdTech platform. The company also secured a $700,000 order for FY26, signaling growing traction in the US education market.

ECS Botanics reports a 5% revenue dip to $19.5 million in FY25 but sees strong B2C growth and record harvest volumes, offset by non-cash impairments.

ECS Botanics Holdings Ltd reported a $5.7 million net loss for FY2025 amid a strategic pivot from B2B to B2C sales and significant impairments. The company aims for a turnaround in FY2026 driven by new product launches and expanded production capacity.

Energy Action Limited reported a robust FY25 with a 12% revenue increase and a 247% jump in statutory profit, underpinned by disciplined expense management and contract growth.

Carbonxt Group Limited reported a 7.1% revenue increase to $16.2 million in FY25 alongside a 16.7% reduction in net loss, while progressing its Kentucky liquid-phase activated carbon facility and navigating ongoing liquidity challenges.

Dubber Corporation Limited reported a 9% increase in revenue to $42.19 million for FY25, alongside a significant reduction in net loss. However, challenges remain with a major contract non-renewal and ongoing efforts to recover $26.6 million in misused funds.

Waypoint REIT reported steady distributable earnings of $55.6 million for the first half of 2025, supported by robust property valuations and disciplined capital management. Despite flat earnings, statutory net profit surged nearly 47%, reflecting significant valuation gains.

Acrux Ltd reported a 44% revenue decline and a modest increase in net loss for FY25, while expanding its US topical generics portfolio and entering the Saudi Arabian market. The company signals a strategic pivot amid intensifying competition and lower returns.

Next Science reports a 42% improvement in adjusted EBITDA loss for 1H FY25 despite a 7% dip in product sales, while shareholders approve a major asset sale to OSARTIS GmbH.

Australian Dairy Nutritionals Group (ASX, AHF) reported a 14% revenue increase to $7.17 million for FY25, driven by a nearly fourfold surge in its infant formula segment, while reducing its net loss by 29%. The company remains debt-free and is expanding its footprint in China and Vietnam.